New Partnership: Bioz Helps DNA Polymerase Technology to Boost Research Visibility Through Interactive Citation Badges
PALO ALTO, CA / ACCESSWIRE / November 19, 2024 / Bioz, Inc., a driving force in AI-enhanced citation tracking, is...
DNA
Fate Therapeutics Highlights FT522 Off-the-shelf, ADR-armed CAR NK Cell Product Candidate at 2024 ACR Convergence
Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens...
Anthos Therapeutics Shares New Analysis from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Substantially Reduced Bleeding in Patients on Antiplatelet Therapy Compared to Rivaroxaban
Data presented at the American Heart Association Scientific Sessions show a 67% reduction in bleeding for patients on antiplatelet therapy...
Precede Biosciences Presents New Data at AACR LBx 2024 Demonstrating an Accurate Readout of Tumor PSMA Expression and Stratification of Response to Lutetium-PSMA in Men with mCRPC from a Simple Blood Test
Results show the potential of a real-time, non-invasive blood test to quantify tumor drug target expression and to stratify therapeutic...
Arbutus’ Imdusiran Achieves Functional Cure in cHBV Patients when Combined with a Short Course of Interferon
50% of patients who had baseline HBsAg levels less than 1000 IU/mL achieved functional cure in Cohort A1 of the...
Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion
Eight participants achieved HBsAg loss at any time.Two participants met criteria for functional cure. Two participants who discontinued NUC therapy...
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared...
Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B
Significantly greater mean declines in HBsAg levels (p <0.017) were seen in those receiving imdusiran, VTP-300 and low-dose nivolumab compared...
CHMP recommends RYBREVANT®▼ (amivantamab) in combination with LAZCLUZE®▼ (lazertinib) for the first-line treatment of patients with EGFR-mutated advanced non-small cell lung cancer
The amivantamab plus lazertinib combination regimen offers potential to provide new standard of care as first-line option for adult patients...
Accelerating Demand for Specialized RCM Solutions in Outpatient and Ancillary Services Set to Surge in 2025, Reports Black Book Research
The U.S. healthcare revenue cycle management (RCM) outsourcing market for outpatient and ancillary services is experiencing significant growth. In 2023,...
90+ CELLARS LAUNCHES NON-ALCOHOLIC SPARKLING WINES
With Growing Demand in Zero Proof and Bubbly Drinks, New Dealcoholized Sparkling Brut and Sparkling Rosé Hit the Spot BOSTON,...
Ginkgo Bioworks Reports Third Quarter 2024 Financial Results
Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions...
Dr. Drew Features Nuvia’s Permanent Teeth in 24 Hours Process
SALT LAKE CITY, Nov. 7, 2024 /PRNewswire/ -- Nuvia Dental Implant Centers, a national leader in advanced dental implant solutions,...
Ginkgo Bioworks Advances Collaboration with Merck to Improve Biologics Manufacturing
BOSTON, Nov. 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and...
Stride Autism Centers Appoints Emily Patrizi as Chief Operating Officer
Leading Company Focused on ABA Therapy for Preschool Children with Autism Expands Leadership TeamCHICAGO, Nov. 12, 2024 (GLOBE NEWSWIRE) --...
NeurAxis Reports Strong Third Quarter 2024 Financial Results Driven by a 40% Increase in Revenues
Conference call will be held today, Tuesday, November 12 at 9:00 am ETCARMEL, Ind., Nov. 12, 2024 (GLOBE NEWSWIRE) --...
LENZ Therapeutics to Participate in Upcoming Investor Conferences
SAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pre-commercial...
Created by the McGill University Health Centre (MUHC) Foundation, the third MUHC’s Got Talent presented by Heritage MD featured performers vying for votes and fundraising for causes at the MUHC
MONTREAL, Nov. 12, 2024 (GLOBE NEWSWIRE) -- MUHC health care staff and supporters took to the stage at Beanfield Theatre...
Actuate Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
Ewing Sarcoma is a Highly Metastatic Form of Sarcoma and the Second Most Prevalent Primary Malignant Tumor in Children and...
Everest Biolabs – Elevating exosome research with new tools to accelerate the development of clinical applications
WALTHAM, Mass., Nov. 11, 2024 /PRNewswire/ -- Everest Biolabs, the life sciences company dedicated to equipping scientists with essential tools for...